Medtronic, Inc.

Dwight H Warkentin

Robert W Stadler

Bozidar Ferek-Petric

Daniel C Sigg

David L Thompson

Tommy Dean Bennett

William J Combs

Catherine R Condie

Roy Christian Martin

Sarah Anne Audet

James Kevin Carney

Li Ping Wang

D Curtis Deno

John D Wahlstrand

Brian Bruce Lee

George J Klein

Anthony J Varrichio

David E Euler

Kenneth M Riff

Michael B Shelton

Glenn C Zillmer

James A Coles, Jr

Gregg Turi

Deborah Ann Jaye

John D Wahlstrandl

A medical device system including a physiological sensor and ultrafiltration unit senses a physiological signal in a patient and computes a fluid status measurement of the patient using the physiological signal. Ultrafiltration therapy is delivered to the patient according to a therapy delivery control parameter established in response to the fluid status measurement.

System and method to regulate ultrafiltration

A method of controlling pulmonary capillary pressure is disclosed which includes increasing the output of a first ventricle (V1) (e.g., a left ventricle) relative to second ventricle (e.g., right ventricle) by increasing the magnitude of a post extrasystolic potentiation (PESP) therapy effect in the first ventricle relative to the magnitude of a PESP therapy effect produced in the second ventricle. In certain embodiments of the invention, this may be accomplished by adjusting the extra-stimulus interval (ESI) in either or both of the left ventricle and the right ventricle, for example.

Method and system for controlling pulmonary capillary pressure

A cardiac ischemic protection system and method for conditioning a patient's heart is provided. The method can include detecting acute myocardial infarction, angina pectoris, silent ischemia, or stunning and providing closed-loop dyssynchronous pacing to the patient's heart to precondition and/or postcondition the patient's heart in order to reduce ischemic damage.

Cardiac protection system and method

Medical devices and methods are used to treat cardiac dysfunction conditions which involve delivery of stimulation pulses in cardiac refractory periods in order to modulate an effective refractory period (ERP). Such devices and methods may be used in conjunction with or in place of other therapies, including increased cardiac contractility (ICC) therapy, post extrasystolic potentiation (PESP) therapy, and other therapies to achieve increased heart contractility, provide a safer and more effective regimen for the corresponding stimulation therapies, and reduce the risk of inducing an arrhythmia.

Method of delivering PESP/ICC as well as adjusting the refractory period of the heart

A closed loop system for monitoring drug dose, intake and effectiveness includes a drug delivery device in data communications with at least one implantable medical device. The system is preferably implemented in a web-enabled environment in which a remote data center communicates with the implantable devices (IMDs) in a patient via a programmer or the pill dispenser. A physician, clinician, or other user may access the remote data center to review and monitor the IMDs or the drug delivery regime remotely. The system further provides a dynamic drug management system, compatible with a web-enabled interactive data communication environment that accurately monitors dose and specific drug effectiveness in a patient to enhance patient care.

Communications system for an implantable medical device and a delivery device

According to the present invention, discrete measurements of fluid pressure development (and derivatives thereof) are used in optimizing hemodynamics for cardiac resynchronization therapy (CRT) delivery and multiple chamber cardiac pacing, and in enhancing hemodynamics in the event of a sub-optimal left-side lead placement. For example, such diverse pressure measurements include: maximum positive or negative dP/dt values, ePAD, RV systolic, RV diastolic, pulse pressure, and the like. According to the present invention, on a periodic basis or upon demand one or more cardiac pacing intervals are iteratively cycled through a predetermined range and the resulting pressure measurements stored for comparison. The cardiac pacing intervals are then adjusted based at least in part upon the most appropriate, or desirable, measured hemodynamics of the patient. The present invention may be implemented as computer readable instructions executed by a microprocessor-based implantable medical device.

Mechanically-based interval optimization for a biventricular pacing engine

A closed loop system for monitoring drug dose, intake and effectiveness includes a pill dispenser in data communications with at least one implantable medical device. The system is preferably implemented in a web-enabled environment in which a remote data center communicates with the implantable devices (IMDs) in a patient via a programmer or the pill dispenser. Th data center includes high speed computers and databases relating to patient history and device information. A physician or clinician may access the remote data center to review and monitor the IMDs remotely. More specifically, the IMDs are adapted to chronically monitor the pill dispenser to thereby log and document drug dose, patient compliance with prescriptive regimens and as well to monitor drug efficacy in the patient. The system further provides a dynamic drug management system, compatible with a web-enabled interactive data communication environment, that accurately monitors dose and specific drug effectiveness in a patient to enhance patient care.

Communications system for an implantable device and a drug dispenser

Multi-site ventricular pacing system measuring QRS duration

An impedance monitor for discerning edema through evaluation of respiratory rate. Preferred embodiment includes edema monitor and trigger to initiate diagnostic reporting or corrective action when activated. Recording of Long Term Average and Short Term Average values for secondary edema measure based on DC signal level are described as are methods and apparatus for removing unwanted recurring noise.

Implantable medical device for measuring time varying physiologic conditions especially edema and for responding thereto

A minimally invasive implant, means for insertion, and description of how to most efficiently use it are described n several embodiments. This implant preferably has a segmented looping memory for storing triggered physiologic events. Preferred events for setting autotriggers to record physiologic signals occurring during events include arrhythmias and syncopal events. Preferably the device can function without a microprocessor. An outside device or other patient activated manual trigger is included. Auto triggers and manually set triggers may be of different sizes. The preferred physiologic events are ECG signals. Electrode spacing can be critical. Additional sensors may be provided to the device. Preferred communications with the device is through telemetry such as is used for pacemakers and other implanted devices.

Minimally invasive implantable device for monitoring physiologic events

Impedance monitor for discerning edema through evaluation of respiratory

Pacemaker designed for support of both orthotopic and heterotopic transplants has three lead bore connector block assembly and dedicated or dedictable amplifiers for pacing and sensing configurations unique to transplant situations. The provision of definable amplifier assignments allows for enhanced sensing, capture detection and therapy.

Apparatus for cardiac pacing in transplant

There is provided a dual chamber pacemaker system and method for ventricular pacing to provide therapy for a patient with cardiomyopathy, this system being characterized by automatically adjusting the AV escape interval so that ventricular pace pulses are delivered at an AV delay which is optimized for HOCM and/or dialated cardiomyopathy therapy. The pacemaker system continually obtains and stores representations of a QRS wave characteristic such as duration, derived either directly from the QRS signal or from an FFRS signal, and compares duration data from one or more cycles to prior stored duration data. The system then adjusts the AV interval as a function of the duration comparison, and the direction of the last adjustment of AV escape interval. By this means, the AV escape interval is maintained at or just short of the onset of fusion, thereby automatically providing for optimally lengthened AV escape intervals consistent with full capture by the delivered ventricular pace pulse.

Growing community of inventors

Arden Hills, MN, United States of America

Dwight H Warkentin